A Study of Tumor Markers to Assess Risk of Recurrence of Liver Cancer After a Liver Transplant

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Jacksonville, Florida: 17-003226
    Sponsor Protocol Number: 17-003226

About this study

The purpose of this study is evaluation of tumoral markers at the time of transplant to assess recurrence risk, and assessment of tumor sensitivity to a panel of candidate therapeutics as a guide to adjunct or therapeutic therapies for recurrent hepatocellular cancers (HCC).  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Patients on the waiting list for liver transplantation with liver cancer, with any etiology
  • Effort will be made to enroll at least 2/3 of patients who have had chronic HCV infection and prior treatment with direct acting antivirals with HCV eradication. 

Exclusion Criteria:

  • Children aged <18 years of age 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Tushar Patel, M.B., Ch.B.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Lori Chase

(904)953-3464

Chase.Lori@mayo.edu

.
CLS-20358837

Mayo Clinic Footer